NN 9277

Drug Profile

NN 9277

Alternative Names: NN9277; NNC 9204 1177

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 16 Oct 2017 Novo Nordisk initiates enrolment in a phase I trial for Obesity (SC) (NCT03308721)
  • 12 Oct 2017 Novo Nordisk plans a phase I trial for Obesity (SC, Injection) (NCT03308721)
  • 30 Sep 2017 Novo Nordisk completes a first-in-human phase I trial for Obesity in USA (SC) (NCT02941042)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top